Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ginkgo Bioworks Holdings, Inc.DNA · Entity 5530 | Director · See remarks | July 28, 2026 | July 30, 2026 |
| SomaLogic, Inc.CMII · Entity 95310 | Director | February 22, 2021 | February 22, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ginkgo Bioworks Holdings, Inc.
Report date July 28, 2026 · Filed July 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 74,258 |
Reported balance
After 2026-07-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-28 · Grant · Acquired 74,258 · Balance 74,258 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest as follows: 75% on October 16, 2026 and 25% on January 21, 2027. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 309,467 |
Reported balance
After 2026-07-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-28 · Grant · Acquired 309,467 · Balance 309,467 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest in equal quarterly installments over the next 12 quarters, with the first vesting to occur on October 16, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest as follows: 75% on October 16, 2026 and 25% on January 21, 2027.
F3: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest in equal quarterly installments over the next 12 quarters, with the first vesting to occur on October 16, 2026.
SomaLogic, Inc.
Report date February 22, 2021 · Filed February 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B common stockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-02-22 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination or earlier at the option of the holder as described under the heading "Description of Securities--Founder Shares" in the Issuer's registration statement on Form S-1 (File No. 333-252626) (the "Registration Statement"), on a one-for-one basis, subject to adjustment for stock splits, stock capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination or earlier at the option of the holder as described under the heading "Description of Securities--Founder Shares" in the Issuer's registration statement on Form S-1 (File No. 333-252626) (the "Registration Statement"), on a one-for-one basis, subject to adjustment for stock splits, stock capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 28, 2026 Filed Jul 30, 2026 20:26 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | GrantRestricted Stock Units · Derivative | 309,467 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-051084 · wk-form4_1785443178.xml · derivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 309,467 Underlying: Class A Common Stock · 309,467 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest in equal quarterly installments over the next 12 quarters, with the first vesting to occur on October 16, 2026. F3 · derivative.expiration_date: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest in equal quarterly installments over the next 12 quarters, with the first vesting to occur on October 16, 2026. Read SEC document |
| July 28, 2026 Filed Jul 30, 2026 20:26 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | GrantRestricted Stock Units · Derivative | 74,258 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-051084 · wk-form4_1785443178.xml · derivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,258 Underlying: Class A Common Stock · 74,258 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest as follows: 75% on October 16, 2026 and 25% on January 21, 2027. F2 · derivative.expiration_date: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest as follows: 75% on October 16, 2026 and 25% on January 21, 2027. Read SEC document |
| April 09, 2026 Filed Apr 10, 2026 21:01 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 109,767 | $6.40 | $702,179.50 |
DisclosureSEC source: 0001628280-26-024743 · wk-form4_1775854893.xml · nonDerivative · entry 4 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 316,483 F2 · kind: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| April 08, 2026 Filed Apr 10, 2026 21:01 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionPerformance-Based Restricted Stock Unit · Derivative | 212,949 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-024743 · wk-form4_1775854893.xml · derivative · entry 6 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 212,949 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance-based restricted stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F1 · kind: Each performance-based restricted stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F1 · price: Each performance-based restricted stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: On June 19, 2025, the Reporting Person was granted 635,670 PSUs based on a company-wide cash flow reduction target over a one-year period beginning on January 1, 2025 and ending on December 31, 2025. The total number of vested PSUs distributed by Issuer on April 7, 2026 and April 8, 2026 in the form of Class A Common Stock reflects actual performance equal to 67% of target performance, as certified by the Compensation Committee of the Board of Directors. F3 · derivative.expiration_date: On June 19, 2025, the Reporting Person was granted 635,670 PSUs based on a company-wide cash flow reduction target over a one-year period beginning on January 1, 2025 and ending on December 31, 2025. The total number of vested PSUs distributed by Issuer on April 7, 2026 and April 8, 2026 in the form of Class A Common Stock reflects actual performance equal to 67% of target performance, as certified by the Compensation Committee of the Board of Directors. Read SEC document |
| April 08, 2026 Filed Apr 10, 2026 21:01 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 97,015 | $6.93 | $672,313.95 |
DisclosureSEC source: 0001628280-26-024743 · wk-form4_1775854893.xml · nonDerivative · entry 3 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 426,250 F2 · kind: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| April 08, 2026 Filed Apr 10, 2026 21:01 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 212,949 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-024743 · wk-form4_1775854893.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 523,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each performance-based restricted stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F1 · price: Each performance-based restricted stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| April 07, 2026 Filed Apr 10, 2026 21:01 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionPerformance-Based Restricted Stock Unit · Derivative | 212,949 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-024743 · wk-form4_1775854893.xml · derivative · entry 5 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,949 Underlying: Class A Common Stock · 212,949 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance-based restricted stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F1 · kind: Each performance-based restricted stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F1 · price: Each performance-based restricted stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: On June 19, 2025, the Reporting Person was granted 635,670 PSUs based on a company-wide cash flow reduction target over a one-year period beginning on January 1, 2025 and ending on December 31, 2025. The total number of vested PSUs distributed by Issuer on April 7, 2026 and April 8, 2026 in the form of Class A Common Stock reflects actual performance equal to 67% of target performance, as certified by the Compensation Committee of the Board of Directors. F3 · derivative.expiration_date: On June 19, 2025, the Reporting Person was granted 635,670 PSUs based on a company-wide cash flow reduction target over a one-year period beginning on January 1, 2025 and ending on December 31, 2025. The total number of vested PSUs distributed by Issuer on April 7, 2026 and April 8, 2026 in the form of Class A Common Stock reflects actual performance equal to 67% of target performance, as certified by the Compensation Committee of the Board of Directors. Read SEC document |
| April 07, 2026 Filed Apr 10, 2026 21:01 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 212,949 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-024743 · wk-form4_1775854893.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 310,316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each performance-based restricted stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F1 · price: Each performance-based restricted stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| April 25, 2024 Filed Apr 29, 2024 20:49 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | GrantStock Option · Derivative | 5,000,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001127602-24-013566 · form4.xml · derivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000,000 Underlying: Class A Common Stock · 5,000,000 shares Expires 2034-04-25 F1 · derivative.exercise_date: The options are subject both to time-based and performance-based vesting criteria (the "Founder Options"). The performance-based vesting is tied to the achievement of four specified stock price hurdles within a five-year period, with 10% of the Founder Options vesting based on the achievement of a 90-calendar-day average stock price of $5.00, 10% of the Founder Options vesting based on the achievement of a 90-calendar-day average stock price of $7.50, 20% of the Founder Options vesting based on the achievement of a 90-calendar-day average stock price of $10.00 and the remaining 60% of the Founder Options vesting based on the achievement of a 90-calendar-day average stock price of $12.50. If any of the performance-based criteria are achieved during the five-year performance period, the awards will vest on the five-year anniversary of the grant date, subject to the Reporting Person's continued employment with Ginkgo on such anniversary. Read SEC document |
| January 04, 2024 Filed Jan 5, 2024 22:11 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.56 | $155,500.00 |
DisclosureSEC source: 0001127602-24-000978 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,894,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.51 to $1.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 22:11 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.54 | $154,400.00 |
DisclosureSEC source: 0001127602-24-000978 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,994,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.51 to $1.615, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| December 21, 2023 Filed Dec 22, 2023 21:57 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.74 | $173,700.00 |
DisclosureSEC source: 0001127602-23-030394 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,094,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.70 to $1.785, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| December 20, 2023 Filed Dec 22, 2023 21:57 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.79 | $179,400.00 |
DisclosureSEC source: 0001127602-23-030394 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,194,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.69 to $1.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| December 14, 2023 Filed Dec 15, 2023 22:05 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,980 | $1.63 | $164,092.50 |
DisclosureSEC source: 0001127602-23-029724 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,294,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.48 to $1.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 22:05 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 99,020 | $1.34 | $132,785.82 |
DisclosureSEC source: 0001127602-23-029724 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,395,660 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.28 to $1.445, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| December 07, 2023 Filed Dec 8, 2023 22:15 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.31 | $131,300.00 |
DisclosureSEC source: 0001127602-23-029166 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,494,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.29 to $1.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| December 06, 2023 Filed Dec 8, 2023 22:15 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.32 | $132,300.00 |
DisclosureSEC source: 0001127602-23-029166 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,594,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.28 to $1.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 30, 2023 Filed Dec 1, 2023 21:59 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.35 | $135,300.00 |
DisclosureSEC source: 0001127602-23-028616 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,694,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.29 to $1.415, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 29, 2023 Filed Dec 1, 2023 21:59 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.45 | $145,200.00 |
DisclosureSEC source: 0001127602-23-028616 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,794,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.39 to $1.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 24, 2023 Filed Nov 27, 2023 21:58 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.41 | $141,300.00 |
DisclosureSEC source: 0001127602-23-028307 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,894,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.37 to $1.455, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 22, 2023 Filed Nov 27, 2023 21:58 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.40 | $140,400.00 |
DisclosureSEC source: 0001127602-23-028307 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,994,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.37 to $1.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 16, 2023 Filed Nov 17, 2023 21:56 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.45 | $145,200.00 |
DisclosureSEC source: 0001127602-23-027852 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,094,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.405 to $1.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 21:56 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.54 | $154,200.00 |
DisclosureSEC source: 0001127602-23-027852 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,194,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.445 to $1.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 09, 2023 Filed Nov 13, 2023 13:01 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.29 | $129,100.00 |
DisclosureSEC source: 0001127602-23-027140 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,294,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.26 to $1.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 13:01 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.50 | $150,200.00 |
DisclosureSEC source: 0001127602-23-027140 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,394,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.48 to $1.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 02, 2023 Filed Nov 3, 2023 21:01 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.52 | $151,600.00 |
DisclosureSEC source: 0001127602-23-026777 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,494,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.39 to $1.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 21:01 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.34 | $134,200.00 |
DisclosureSEC source: 0001127602-23-026777 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,594,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.31 to $1.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| October 26, 2023 Filed Oct 27, 2023 20:53 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.46 | $145,900.00 |
DisclosureSEC source: 0001127602-23-026331 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,694,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.43 to $1.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| October 25, 2023 Filed Oct 27, 2023 20:53 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.48 | $147,600.00 |
DisclosureSEC source: 0001127602-23-026331 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,794,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.41 to $1.535 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| October 19, 2023 Filed Oct 20, 2023 20:54 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.61 | $160,600.00 |
DisclosureSEC source: 0001127602-23-026119 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,894,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.555 to $1.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| October 18, 2023 Filed Oct 20, 2023 20:54 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.69 | $169,000.00 |
DisclosureSEC source: 0001127602-23-026119 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,994,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.65 to $1.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| October 12, 2023 Filed Oct 13, 2023 21:02 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.66 | $165,600.00 |
DisclosureSEC source: 0001127602-23-025844 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,094,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.61 to $1.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| October 11, 2023 Filed Oct 13, 2023 21:02 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.76 | $175,600.00 |
DisclosureSEC source: 0001127602-23-025844 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,194,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.715 to $1.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| October 05, 2023 Filed Oct 6, 2023 21:07 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.67 | $166,600.00 |
DisclosureSEC source: 0001127602-23-025689 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,294,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.615 to $1.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| October 04, 2023 Filed Oct 6, 2023 21:07 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.62 | $161,600.00 |
DisclosureSEC source: 0001127602-23-025689 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,394,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.56 to $1.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| September 28, 2023 Filed Sep 29, 2023 21:01 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.75 | $174,900.00 |
DisclosureSEC source: 0001127602-23-024881 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,494,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.705 to $1.795, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| September 27, 2023 Filed Sep 29, 2023 21:01 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.83 | $182,500.00 |
DisclosureSEC source: 0001127602-23-024881 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,594,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.75 to $2.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| September 21, 2023 Filed Sep 22, 2023 21:01 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.77 | $176,600.00 |
DisclosureSEC source: 0001127602-23-024678 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,694,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.75 to $1.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| September 20, 2023 Filed Sep 22, 2023 21:01 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.84 | $183,800.00 |
DisclosureSEC source: 0001127602-23-024678 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,794,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.81 to $1.885 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| September 14, 2023 Filed Sep 15, 2023 20:52 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $2.00 | $199,500.00 |
DisclosureSEC source: 0001127602-23-024231 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,894,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.95 to $2.075 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| September 13, 2023 Filed Sep 15, 2023 20:52 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $2.04 | $204,300.00 |
DisclosureSEC source: 0001127602-23-024231 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,994,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.02 to $2.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| September 07, 2023 Filed Sep 8, 2023 21:01 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $2.13 | $213,300.00 |
DisclosureSEC source: 0001127602-23-023917 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,094,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.09 to $2.175, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| September 06, 2023 Filed Sep 8, 2023 21:01 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $2.23 | $222,900.00 |
DisclosureSEC source: 0001127602-23-023917 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,194,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.185 to $2.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| August 31, 2023 Filed Sep 1, 2023 20:43 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $2.29 | $229,200.00 |
DisclosureSEC source: 0001127602-23-023598 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,294,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.235 to $2.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| August 30, 2023 Filed Sep 1, 2023 20:43 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $2.22 | $221,500.00 |
DisclosureSEC source: 0001127602-23-023598 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,394,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.12 to $2.275, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| August 24, 2023 Filed Aug 25, 2023 21:16 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.70 | $169,800.00 |
DisclosureSEC source: 0001127602-23-023257 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,494,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.66 to $1.825, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 21:16 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.74 | $173,800.00 |
DisclosureSEC source: 0001127602-23-023257 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,594,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.66 to $1.795, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| August 17, 2023 Filed Aug 18, 2023 20:52 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.64 | $163,800.00 |
DisclosureSEC source: 0001127602-23-022952 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,694,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.59 to $1.685, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 20:52 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.68 | $167,800.00 |
DisclosureSEC source: 0001127602-23-022952 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,794,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.63 to $1.755, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| August 10, 2023 Filed Aug 11, 2023 21:02 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.76 | $176,400.00 |
DisclosureSEC source: 0001127602-23-022386 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,894,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.705 to $1.91, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.